CYTOSORBENTS CORPORATION (CTSO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 24.02M USD | Liabilities, Current |
| Cash and equivalents | 4.41M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 6.79M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 3.69M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $24.02M | $4.41M | (m) | $6.79M | $3.69M | (m) |
| 2026-03-31 | (m) | $16.30M | $4.81M | (m) | $7.15M | $4.48M | (m) |
| 2025-12-31 | (m) | $9.71M | $6.25M | (m) | $7.55M | $5.28M | (m) |
| 2025-09-30 | (m) | $10.11M | $7.54M | (m) | $7.43M | $4.00M | (m) |
| 2025-06-30 | (m) | $9.84M | $10.20M | (m) | $7.74M | $3.71M | (m) |
| 2025-03-31 | (m) | $9.74M | $11.59M | (m) | $7.67M | $3.02M | (m) |
| 2024-12-31 | (m) | $9.82M | $3.28M | (m) | $7.32M | $2.73M | (m) |
| 2024-09-30 | (m) | $8.43M | $5.69M | (m) | $6.63M | $3.25M | (m) |
| 2024-06-30 | (m) | $10.34M | $8.46M | (m) | $7.82M | $4.32M | (m) |
| 2024-03-31 | (m) | $13.42M | $8.61M | (m) | $6.77M | $3.74M | (m) |
| 2023-12-31 | (m) | $14.55M | $14.13M | (m) | $6.06M | $3.68M | (m) |
| 2023-09-30 | (m) | $11.97M | $8.36M | (m) | $6.18M | $2.98M | (m) |
| 2023-06-30 | (m) | $10.35M | $13.15M | (m) | $7.02M | $2.05M | (m) |
| 2023-03-31 | (m) | $10.44M | $19.05M | (m) | $5.53M | $1.73M | (m) |
| 2022-12-31 | (m) | $9.71M | $22.14M | (m) | $5.66M | $3.46M | (m) |
| 2022-09-30 | (m) | $10.12M | $22.55M | (m) | $4.96M | $3.54M | (m) |
| 2022-06-30 | (m) | $10.55M | $30.16M | (m) | $5.17M | $4.98M | (m) |
| 2022-03-31 | (m) | $14.67M | $43.02M | (m) | $4.58M | $5.45M | (m) |
| 2021-12-31 | (m) | $13.69M | $52.14M | (m) | $4.52M | $4.77M | (m) |
| 2021-09-30 | (m) | $11.07M | $61.04M | (m) | $5.24M | $4.53M | (m) |
| 2021-06-30 | (m) | $10.80M | $65.61M | (m) | $5.75M | $3.69M | (m) |
| 2021-03-31 | (m) | $9.76M | $68.47M | (m) | $5.02M | $3.11M | (m) |
| 2020-12-31 | (m) | $10.15M | $71.42M | (m) | $5.16M | $2.67M | (m) |
| 2020-09-30 | (m) | $17.36M | $87.98M | (m) | $5.80M | $2.02M | (m) |
| 2020-06-30 | (m) | $15.66M | $35.11M | (m) | $3.89M | $1.99M | (m) |
| 2020-03-31 | (m) | $11.46M | $26.39M | (m) | $5.40M | $1.97M | (m) |
| 2019-12-31 | (m) | $9.94M | $12.23M | (m) | $4.47M | $2.11M | (m) |
| 2019-09-30 | (m) | $9.30M | $15.98M | (m) | $3.45M | $1.77M | (m) |
| 2019-06-30 | (m) | $6.92M | $16.34M | (m) | $3.45M | $1.46M | (m) |
| 2019-03-31 | (m) | $6.71M | $19.65M | (m) | $3.27M | $1.21M | (m) |
| 2018-12-31 | (m) | $6.54M | $22.37M | (m) | $3.94M | $833.13K | (m) |
| 2018-09-30 | (m) | $4.26M | $24.91M | (m) | $3.64M | $779.42K | (m) |
| 2018-06-30 | (m) | $3.49M | $25.28M | (m) | $2.90M | $769.25K | (m) |
| 2018-03-31 | (m) | $3.99M | $21.09M | (m) | $2.35M | $680.18K | (m) |
| 2017-12-31 | (m) | $7.85M | $17.32M | (m) | $2.21M | $795.66K | (m) |
| 2017-09-30 | (m) | $5.78M | $15.40M | (m) | $2.35M | $1.09M | (m) |
| 2017-06-30 | (m) | $6.23M | $16.40M | (m) | $2.06M | $889.74K | (m) |
| 2017-03-31 | (m) | $6.18M | $3.24M | (m) | $1.73M | $857.79K | (m) |
| 2016-12-31 | (m) | $6.09M | $5.25M | (m) | $1.43M | $833.98K | (m) |
| 2016-09-30 | (m) | $5.00M | $6.38M | (m) | $1.41M | $1.05M | (m) |
| 2016-06-30 | (m) | $3.93M | $8.67M | (m) | $944.78K | $1.05M | (m) |
| 2016-03-31 | (m) | $3.25M | $3.54M | (m) | $760.16K | $1.06M | (m) |
| 2015-12-31 | (m) | $3.04M | $5.32M | (m) | $648.87K | $1.19M | (m) |
| 2015-09-30 | (m) | $3.45M | $7.39M | (m) | $553.38K | $1.34M | (m) |
| 2015-06-30 | (m) | $2.53M | $8.02M | (m) | (m) | $1.06M | (m) |
| 2015-03-31 | (m) | $6.20M | $10.42M | (m) | (m) | $702.92K | (m) |
| 2014-12-31 | (m) | $4.51M | $3.61M | (m) | (m) | $537.57K | (m) |
| 2014-09-30 | (m) | $1.55M | $433.42K | (m) | (m) | $387.07K | (m) |
| 2014-06-30 | (m) | $2.77M | $4.88M | (m) | (m) | $303.69K | (m) |
| 2014-03-31 | (m) | $3.30M | $6.42M | (m) | (m) | $146.52K | (m) |
| 2013-12-31 | (m) | $3.06M | $2.18M | (m) | (m) | $245.61K | (m) |
| 2013-09-30 | (m) | $3.07M | $2.35M | (m) | (m) | $362.54K | (m) |
| 2013-06-30 | (m) | $2.10M | $1.87M | (m) | (m) | $476.55K | (m) |
| 2013-03-31 | (m) | $993.43K | $1.37M | (m) | (m) | $555.26K | (m) |
| 2012-12-31 | (m) | $2.08M | $1.73M | (m) | (m) | $682.37K | (m) |
| 2012-09-30 | (m) | $2.08M | $2.06M | (m) | (m) | $625.78K | (m) |
| 2012-06-30 | (m) | $2.30M | $1.74M | (m) | (m) | $535.26K | (m) |
| 2012-03-31 | (m) | $2.25M | $1.80M | (m) | $39.79K | $468.56K | (m) |
| 2011-12-31 | (m) | $1.53M | $1.19M | (m) | $36.08K | $431.02K | (m) |
| 2011-09-30 | (m) | $1.59M | $2.30M | (m) | (m) | $186.34K | (m) |
| 2011-06-30 | (m) | $1.42M | $3.42M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $2.44M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.22M | $1.06M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $758.22K | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $595.52K | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.60M | (m) | (m) | (m) | (m) |
| 1997-01-21 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |